4HF Biotec

4HF Biotec

Halle, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

4HF Biotec is a private, preclinical-stage biotech leveraging a unique AI-driven in silico platform, the 4HF CancerDataMiner™, to discover and develop novel small molecule drug conjugates (SMDCs) for oncology. The company operates a hybrid business model, advancing its own pipeline while offering in silico research services to industry partners. Its lead project, SELECTHERA, is a collaboration with the German Cancer Research Center (DKFZ/DKTK) focused on developing tumor-selective toxins and radioligands for prostate and lung cancer.

Oncology

Technology Platform

4HF CancerDataMiner™ - a proprietary in silico platform that synergizes multi-omics cancer data, computational sciences, and AI-driven drug discovery to identify novel cancer-specific targets and associated small molecule effectors.

Opportunities

The large and growing market for targeted cancer therapies, especially in difficult-to-treat solid tumors, presents a significant opportunity.
The company's focus on Small Molecule Drug Conjugates (SMDCs) addresses limitations of antibody-drug conjugates (ADCs), potentially offering better tumor penetration and lower immunogenicity in a less crowded field.

Risk Factors

High preclinical risk as drug candidates may fail in development.
The company is dependent on securing substantial future funding to advance its pipeline into clinical trials.
It operates in the highly competitive oncology space against larger, well-resourced companies.

Competitive Landscape

4HF competes in the targeted oncology space, primarily against developers of Antibody-Drug Conjugates (ADCs) and other biotechs exploring Small Molecule Drug Conjugates (SMDCs). Its differentiation lies in its AI/omics-driven discovery platform and its specific focus on novel SMDCs for solid tumors.